Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Pfizer’s Shareholders and AstraZeneca’s

    The Financial Times is out with an editorial denouncing Pfizer’s attempted takeover of AstraZeneca. It’s definitely worth a read for the case it makes. What’s a drug company supposed to be doing, anyway? But (the effect on British research) is not the only big question requiring discussion. Another is the extent to which the board… Read More
  • Business and Markets

    Pfizer-AZ: Politics and Press Releases

    This saga is going to be running for a while; we might as well all resign ourselves to it. The latest seems to be that the British government is getting more visibly into the act. The Business Secretary, Vince Cable, has said that he’s not going to let Pfizer use the UK as a tax… Read More
  • Business and Markets

    The Lessons of Intercept and NASH

    Over at LifeSciVC, Tom Hughes has a post about Intercept Pharmaceuticals and their wild ride with an FXR ligand for non-alcoholic steatohepatitis (NASH). Anyone who owned ICPT will recall that period vividly, since the positive news from the clinical trial sent the company’s stock from an already-not-cheap $72/share to a where’s-the-oxy… Read More
  • Business and Markets

    AstraZeneca: Don’t Buy Us

    After Pfizer’s less-than-wonderful earnings report yesterday, AstraZeneca is out today painting a picture of how great things will be if they don’t get swallowed by them. John Carroll at FierceBiotech has the details, but I especially enjoyed his pithy comment on Twitter: “AZN made more promises today than I will ever see broken a… Read More
  • Business and Markets

    Fast Money, But What Direction Is It Going?

    If you’re inclined to get your financial info from fast-talking analysts on cable news channels, you might want to give this blog post a read. The author points out several egregious mistakes that CNBC’s “Fast Money” has made with biotech/pharma stocks by having traders giving out advice and forecasts despite apparently know… Read More
  • Business and Markets

    Pfizer/AstraZeneca: Asymmetric Cuts Look Likely

    So Pfizer is out today with some pretty bad financials, which are doubtless one reason for their determination to Go Out and Buy Somebody, whether they’re an R&D powerhouse or not. They’ve also been reassuring the British government that they’ll go ahead with the Cambridge research construction that AstraZeneca has begun, and… Read More
  • Business and Markets

    Some People at Pfizer Whose Fault This Isn’t

    It’s worth keeping in mind, as the Pfizer/AZ story develops, that there are some people that don’t get mentioned who aren’t enjoying this, either: the scientists in Pfizer’s labs. As I’ve mentioned, I know folks there, and I know that there are (still) an awful lot of good scientists working there. And they, of course… Read More
  • Business and Markets

    Allergan: “Golf-Course Deprived”

    Here’s a good one for you. Valeant is well-known as an outfit that largely scorns R&D, and cuts it whenever they buy someone. They do mergers and acquisitions to get the fruits of someone else’s research instead. You know, sort of a mini-Pfizer. (If anyone at Pfizer is offended by that comparison, they should take… Read More
  • Business and Markets

    AstraZeneca Tell Pfizer to Buzz Off

    That’s what I gather from this report, anyway. Reports had leaked out that Pfizer was going to make a higher offer for AZ shares, and that happened earlier this morning. But AstraZeneca’s board has turned it down flat, saying that it undervalues the company and “is not an adequate basis” for further discussions. You’d… Read More
  • Business and Markets

    Can Anything Stop Pfizer-AstraZeneca From Going Through?

    At FierceBiotech, John Carroll asks the question that’s on a lot of drug-industry minds this week: can anything stop Pfizer’s takeover of AstraZeneca? There are a few possibilities, but overall, it comes down to how much money Pfizer wants to spend. If they open their wallet far enough, they can buy most anyone they want. Read More
...293031...